Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin

International Journal of Cancer

Volumn 104, Issue 3, 2003, Pages 289-302

  Suzuki, Mika ^a   Kobayashi, Hiroshi ^a   Tanaka, Yoshiko ^a   Hirashima, Yasuyuki ^a   Kanayama, Naohiro ^a   Takei, Yuji ^b   Saga, Yasushi ^b   Suzuki, Mitsuaki ^b   Itoh, Hiroshi ^c   Terao, Toshihiko ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Bikunin; Invasion; Transfection; Urinary trypsin inhibitor; Urokinase type plasminogen activator

Indexed keywords

GELATINASE A; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; TRYPSIN; ULINASTATIN; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CARCINOMATOUS PERITONITIS; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CARCINOMA; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MAP KINASE SIGNALING SYSTEM; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PANCREATIC ELASTASE; PERITONEAL NEOPLASMS; PLASMIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERINE PROTEINASE INHIBITORS; TRANSFECTION; TRYPSIN; TRYPSIN INHIBITOR, KUNITZ SOYBEAN; TUMOR CELLS, CULTURED;

EID: 0037431429     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10950     Document Type: Article

References (49)

1. Kohn EC, Llotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995;55:1856-62.
2. Crowe DL, Shuler CF. Regulation of tumor cell invasion by extracellular matrix. Histol Histopathol 1999;14:665-71.
3. Pappot H, Brunner N. The plasminogen activation system and its role in lung cancer. Lung Cancer 1995;12:1-12.
4. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999;13:781-92.
5. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M. Multifunctional potential of the plasminogen activator system in tumor invasion and metastasis (review). Int J Oncol 1998;13:893-906.
6. Kobayashi H, Suzuki K, Sugino D, Terao T. Urinary trypsin inhibitor levels in amniotic fluid of normal human pregnancy: decreased levels observed at parturition. Am J Obstet Gynecol 1999;180:141-7.
7. Kobayashi H, Fujie M, Shinohara H, Ohi H, Sugimura M, Terao T. Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cells. Int J Cancer 1994;57:378-84.
8. Kobayashi H, Shinohara H, Ohi H, Sugimura M, Terao T, Fujie M. Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion. Clin Exp Metastasis 1994;12:117-28.
9. Kobayashi H, Shinohara H, Takeuchi K, Itoh M, Fujie M, Saitoh M, Terao T. Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis. Cancer Res 1994;54:844-9.
10. Kobayashi H, Gotoh J, Fujie M, Terao T. Characterization of the cellular binding site for the urinary trypsin inhibitor. J Biol Chem 1994;269:20642-7.
11. Kobayashi H, Gotoh J, Hirashima Y, Fujie M, Sugino D, Terao T. Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J Biol Chem 1995;270:8361-6.
12. Kobayashi H, Gotoh J, Kanayama N, Hirashima Y, Terao T, Sugino D. Inhibition of tumor cell invasion through matrigel by a peptide derived from the domain II region in urinary trypsin inhibitor. Cancer Res 1995;55:1847-52.
13. Kobayashi H, Shinohara H, Fujie M, Gotoh J, Itoh M, Takeuchi K, Terao T. Inhibition of metastasis of Lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis models. Int J Cancer 1995;63:455-62.
14. Kobayashi H, Shinohara H, Gotoh J, Fujie M, Fujishiro S, Terao T. Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent. Br J Cancer 1995;72:1131-7.
15. Kobayashi H, Suzuki M, Tanaka Y, Hirashima Y, Terao T. Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C and MEK/ERK/c-Jun-dependent signaling pathways. J Biol Chem 2001;276:2015-22.
16. Kobayashi H, Gotoh J, Terao T. Urinary trypsin inhibitor efficiently inhibits urokinase production in tumor necrosis factor-stimulated cells. Eur J Cell Biol 1996;71:380-6.
17. Kobayashi H, Sugino D, She MY, Ohi H, Hirashima Y, Shinohara H, Fujie M, Shibata K, Terao T. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis. Eur J Biochem 1998;253:817-26.
18. Kobayashi H, Hirashima Y, Sun GW, Fujie M, Shibata K, Tamotsu S, Miura K, Sugino D, Tanaka Y, Kondo S, Terao T. Identification and characterization of the cell-associated binding protein for urinary trypsin inhibitor. Biochim Biophys Acta 1998;1383:253-68.
19. Sugino D, Okushima M, Kobayashi H, Terao T. Production of a hybrid protein consisting of the N-terminal fragment of urokinase and the C-terminal domain of urinary trypsin inhibitor in Escherichia coli. Biotechnol Appl Biochem 1998;27:145-52.
20. Kobayashi H, Suzuki M, Sun GW, Hirashima Y, Terao T. Suppression of urokinase-type plasminogen activator expression from human ovarian cancer cells by urinary trypsin inhibitor. Biochim Biophys Acta 2000;1481:310-6.
21. Kobayashi H, Hirashima Y, Terao T. Human myometrial cells in culture express specific binding sites for urinary trypsin inhibitor. Mol Hum Reprod 2000;6:101-8.
22. Kobayashi H, Hirashima Y, Sun GW, Fujie M, Nishida T, Takigawa M, Terao T. Identity of urinary trypsin inhibitor-binding protein with link protein. J Biol Chem 2000;275:21185-91.
23. Kikuchi Y, Kizawa I, Oomori K, Miyauchi M, Kita T, Sugita M, Tenjin Y, Kato K. Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation. Cancer Res 1987:47:592-6.
24. Urabe M, Hasumi Y, Ogasawara Y, Matsushita T, Kamoshita N, Nomoto A, Colosi P, Kurtzman GJ, Tobita K, Ozawa K. A novel dicistronic AAV vector using a short IRES segment derived from hepatitis C virus genome. Gene 1997;200:157-62.
25. Wigler M, Pellicer A, Silverstein S, Axel R. Biochemical transfer of single-copy eucaryotic genes using total cellular DNA as donor. Cell 1978;14:725-31.
26. Chen YT, Holcomb C, Moore HP. Expression and localization of two low molecular weight GTP-binding proteins, Rab8 and Rab10, by epitope tag. Proc Natl Acad Sci USA 1993;90:6508-12.
27. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
28. Mizushima S, Nii A, Kato K, Uemura A. Gene expression of the two heavy chains and one light chain forming the inter-α-trypsin-inhibitor in human tissues. Biol Pharm Bull 1998;21:167-9.
29. Proksch GJ, Routh JI. The purification of the trypsin inhibitor from human pregnancy urine. J Lab Clin Med 1972;79:491-9.
30. Hochstrasser K, Wachter E. Kunitz-type proteinase inhibitors derived by limited proteolysis of the inter-alpha-trypsin inhibitor, I. Determination of the amino acid sequence of the antitryptic domain by solid-phase Edman degradation. Hoppe-Seylers Z Physiol Chem 1979;360:1285-96.
31. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
32. Buttke TM, Mcbrey JA, Owen TC. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J Immunol Methods 1993;157:233-40.
33. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45.
34. Giancotti FG, Ruoslahti E. Elevated levels of the α5β1 receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 1990;60:849-59.
35. Parangi S, O'Reilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J, Hanahan D. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 1996;93:2002-7.
36. Seddighzadeh M, Zhou JN, Kronenwett U, Shoshan MC, Auer G. Sten-Linder M, Wiman B, Linder S. ERK signaling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. Clin Exp Metastasis 1999;17:649-54.
37. Suzuki M. Kobayashi H, Tanaka Y. Hirashima Y, Terao T. Structure and function analysis of urinary trypsin inhibitor (UTI): identification of binding domains and signaling property of UTI by analysis of truncated proteins. Biochim Biophys Acta 2001;1547:26-36.
38. Hirashima Y, Kobayashi H, Suzuki M, Tanaka Y, Kanayama N, Fujie M, Nishida T, Takigawa M, Terao T. Characterization of binding properties of urinary trypsin inhibitor to cell-associated binding sites on human chondrosarcoma cell line HCS-2/8. J Biol Chem 2001;276:13650-6.
39. Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Gunzler WA, Janicke F, Graeff H. Cathepsin B efficiently activates the soluble and tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J Biol Chem 1991;266:5147-52.
40. Liotta LA. Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 1986;46:1-7.
41. Mohler JL, Partin AW, Isaacs JT, Coffey DS. Metastatic potential prediction by a visual grading system of cell motility: prospective validation in the Dunning R-3327 prostatic adenocarcinoma model. Cancer Res 1988;48:4312-7.
42. Partin AW, Schoeniger JS, Mohler JL, Coffey DS. Fourier analysis of cell motility: correlation of motility with metastatic potential. Proc Natl Acad Sci USA 1989;86:1254-8.
43. Muehlenweg B, Assfalg-Machleidt I, Parrado SG, Burgle M, Creutzburg S, Schmitt M, Auerswald EA. Machleidt W, Magdolen V. A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site. J Biol Chem 2000;275:33562-6.
44. Schwartz BS. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism. J Biol Chem 1994;269:8319-23.
45. Wilhelm O, Weidle U, Hohl S, Rettenberger P, Schmitt M, Graeff H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett 1994;337:131-4.
46. Alonso DF, Tejera AM, Farias EF, Bal de Kier Joffe E, Gomez DE. Inhibition of mammary tumor cell adhesion, migration and invasion by the selective synthetic urokinase inhibitor B428. Anticancer Res 1998;18:4499-504.
47. Burgle M, Koppitz M, Riemer C, Kessler H, Konig B, Weidle UH, Kellermann J, Lottspeich F, Graeff H, Schmitt M, Goretzki L. Reuning U, Wilhelm O. Magdolen V. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Biol Chem 1997;378:231-7.
48. Kook YH, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 1994;13:3983-91.
49. Zhu F, Jia S, Xing G, Gao L, Zhang L, He F. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis. DNA Cell Biol 2001;20:297-305.